Envestnet Asset Management
GPCR icon

Envestnet Asset Management’s Structure Therapeutics GPCR Stock Holding History

Envestnet Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$621K Buy
11,575
+198
+2% +$8.76K ﹤0.01% 3924
2026
Q1 		$548K Sell
11,377
-193
-2% -$13.2K ﹤0.01% 3868
2025
Q4 		$805K Sell
11,570
-650
-5% -$26.5K ﹤0.01% 3393
2025
Q3 		$342K Buy
12,220
+1,544
+14% +$30.8K ﹤0.01% 3996
2025
Q2 		$221K Buy
+10,676
New +$235K ﹤0.01% 4186
2025
Q1 		– Sell
-7,403
Closed -$201K – 4395
2024
Q4 		$201K Buy
7,403
+843
+13% +$29.9K ﹤0.01% 4099
2024
Q3 		$288K Sell
6,560
-3,220
-33% -$125K ﹤0.01% 3849
2024
Q2 		$384K Buy
9,780
+4,623
+90% +$190K ﹤0.01% 3591
2024
Q1 		$221K Buy
+5,157
New +$217K ﹤0.01% 3898

Other funds holding GPCR

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
TI
TrueMark Investments Chicago, Illinois $798M AUM 25.52% 1-Year Est. Return

Envestnet Asset Management's GPCR Position: Q2 2026 in Review

Envestnet Asset Management increased its Structure Therapeutics (GPCR) stake by 1.7% in Q2 2026, buying an estimated $8.76K and bringing the position to 11,575 shares worth $621K. The position accounts for ﹤0.01% of the portfolio, ranked #3924.

Envestnet Asset Management first reported a position in GPCR in Q1 2024 and has held it in 9 quarters since. The position peaked at $805K in Q4 2025. 45 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Envestnet Asset Management held 11,575 shares of Structure Therapeutics worth $621K as of Q2 2026.
  • Envestnet Asset Management bought 198 Structure Therapeutics shares in Q2 2026, an estimated $8.76K.
  • Structure Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3924 holding.
  • Envestnet Asset Management first reported a position in Structure Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Envestnet Asset Management's Structure Therapeutics position peaked at $805K in Q4 2025.
  • 45 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.